Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Fineline Cube Mar 2, 2026
Company Drug

InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label

Fineline Cube Mar 2, 2026
Company Deals

Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes

Fineline Cube Jan 11, 2025

Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...

Company Deals

Immunochina Pharmaceuticals Raises Series E Funding for CAR-T Therapy IM19

Fineline Cube Jan 11, 2025

Beijing-based biotech Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series...

Company Drug

Sinogen’s SalMet-Vec Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jan 10, 2025

China’s oncology specialist Guangzhou Sinogen Pharmaceutical Co., Ltd. has announced receiving Orphan Drug Designation (ODD)...

Legal / IP

SynCardia’s Next-Generation Artificial Heart Granted Patent in China

Fineline Cube Jan 10, 2025

US-based SynCardia Systems, LLC., a global leader in total artificial heart technology, has announced that...

Company Deals

Zai Lab and MediLink Therapeutics Partner to Develop LRRC15 ADC Drug ZL-6201 for Solid Tumors

Fineline Cube Jan 10, 2025

On January 10, Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced a new strategic cooperation...

Company Deals

Danaher Corporation Partners with Innovaccer to Enhance Healthcare AI Solutions

Fineline Cube Jan 10, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced an investment partnership...

Company Drug

Sanofi’s Sarclisa Meets Co-Primary Endpoints in Phase III IRAKLIA Study for Multiple Myeloma

Fineline Cube Jan 10, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY, EPA: SAN) has announced that the Phase III IRAKLIA...

Company Drug

FDA Grants Priority Review to Johnson & Johnson’s Nipocalimab for Myasthenia Gravis

Fineline Cube Jan 10, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced that the US FDA has granted...

Company Deals

Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio

Fineline Cube Jan 10, 2025

German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from...

Company Deals

Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments

Fineline Cube Jan 10, 2025

UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co....

Company Medical Device

Roche Gains FDA 510(k) Clearance for Roche Digital Pathology Dx with VENTANA DP 600

Fineline Cube Jan 10, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced an additional 510(k) clearance from the...

Company Deals

TCMTech Files for IPO on Hong Kong Stock Exchange, Showcasing TCM AI Leadership

Fineline Cube Jan 10, 2025

China-based TCMTech Inc., recognized as the largest artificial intelligence (AI) empowered traditional Chinese medicine (TCM)...

Company Deals

Verdiva Bio Launches with USD 411 Million Series A Financing for Biopharma Development

Fineline Cube Jan 10, 2025

UK-based Verdiva Bio Limited has announced its launch as a clinical-stage biopharma company, backed by...

Company Deals

ImmVira Partners with Merz Aesthetics to Develop Anti-Wrinkle Exosome Products

Fineline Cube Jan 10, 2025

Shenzhen-based ImmVira’s exosomes-focused subsidiary has struck a partnership with US leading firm Merz Aesthetics. The...

Company Deals

SciWind Bio and Verdiva Bio Partner on Global Development of Obesity Therapies

Fineline Cube Jan 10, 2025

On January 10, SciWind Bio announced a global development and commercialization license and collaboration agreement...

Company Deals

MediLink and Zai Lab Collaborate on LRRC15-Targeted ADC Drug ZL-6201

Fineline Cube Jan 10, 2025

Chinese biotechs MediLink Therapeutics (Suzhou) Co., Ltd and Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688)...

Company Drug

Bayer’s Elinzanetant Meets All Primary Endpoints in Phase III OASIS 4 Study

Fineline Cube Jan 10, 2025

Germany-based Bayer AG (ETR: BAYN) has announced that the Phase III OASIS 4 study for...

Company Drug

Inmagene Biopharmaceuticals Posts Positive Results for IMG-007 in Atopic Dermatitis

Fineline Cube Jan 10, 2025

Inmagene Biopharmaceuticals, a Sino-US biotech that recently merged with US-based Ikena Oncology, Inc. (NASDAQ: IKNA),...

Company Deals

BrainAurora Medical Technology IPOs on Hong Kong Stock Exchange

Fineline Cube Jan 10, 2025

Zhejiang-based BrainAurora Medical Technology Limited (HKG: 6681), the first company in China to combine neuroscience...

Policy / Regulatory

NMPA Releases 89th Batch of Reference Drugs for GQCE Work

Fineline Cube Jan 10, 2025

The National Medical Products Administration (NMPA) has released the 89th batch of reference drugs for...

Posts pagination

1 … 192 193 194 … 628

Recent updates

  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
  • Sino Biopharma’s Rovadicitinib Wins NMPA Approval – First‑in‑Class JAK/ROCK Inhibitor for Myelofibrosis
  • Antengene’s XPOVIO Secures Second South Korea Reimbursement – Selinexor Combo Approved for Multiple Myeloma
  • Hangyu Pharma’s Sosimerasib Wins NMPA Approval – First KRAS G12C Inhibitor for Post‑Therapy NSCLC in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Company Drug

InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label

Company Drug

Sino Biopharma’s Rovadicitinib Wins NMPA Approval – First‑in‑Class JAK/ROCK Inhibitor for Myelofibrosis

Company Drug

Antengene’s XPOVIO Secures Second South Korea Reimbursement – Selinexor Combo Approved for Multiple Myeloma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.